CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 100 enrolled
Drug / intervention
Control group-Blood sampling +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02364154
NCT02364154N/ACompleted
CompareCT.gov

Metabolic Phenotyping of Blood Plasma by Means of 1H-NMR Spectroscopy: a New Tool to Detect Colorectal Cancer?

Hasselt University·observational·Posted Feb 16, 2015·Updated Aug 21, 2018

In Brief

An observational study evaluating Control group-Blood sampling and Blood sampling for Colorectal Cancer. Completed, enrolled 100 participants across 1 site.

Detailed Summary

The hypothesis of the present study is that metabolic phenotyping of blood plasma allows to (i) discriminate between colorectal cancer patients and control subjects and (ii) identify new biomarkers for colorectal cancer. In order to test this hypothesis, the investigators will apply proton nuclear magnetic resonance (1H-NMR) spectroscopy to perform metabolic phenotyping of blood plasma in 50 colorectal cancer patients and 50 control subjects. Multivariate statistics will be performed to assess the discriminative power of the applied methodology in distinguishing between both groups and to identify metabolites with potential as biomarkers for colorectal cancer.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesBelgium
CollaboratorsZiekenhuis Oost-Limburg

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 16, 2015
Enrollment StartDec 1, 2014
Primary CompletionJun 1, 2015
Study CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 11.4 years ago

Interventions

Control group-Blood samplingother

Determine the metabolic phenotype of blood plasma by NMR spectroscopy

Blood samplingother

determine amount and type of free circulating miRNA in blood plasma